UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Spruce Biosciences, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

85209E109

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- $\square \qquad \text{Rule 13d-1(b)}$
- \boxtimes Rule 13d-1(c)
- $\square \qquad \text{Rule 13d-1(d)}$

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 85209E109 1 Names of Reporting Persons 5AM Opportunities II, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) \boxtimes (1) SEC Use Only 3. 4. Citizenship or Place of Organization Delaware 5. Sole Voting Power 0 Number of 6. Shared Voting Power Shares Beneficially 1,773,000 shares (2) Owned by 7. Sole Dispositive Power Each Reporting 0 Person With 8. Shared Dispositive Power 1,773,000 shares (2) 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,773,000 shares (2) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 4.1% (3) 12. Type of Reporting Person (See Instructions) PN

- (1) This Schedule 13G is filed by 5AM Opportunities II, L.P. ("Opps II"), 5AM Opportunities II (GP), LLC ("Opps II GP"), Dr. Kush Parmar ("Parmar") and Andrew J. Schwab ("Schwab" and, with Opps II, Opps II GP and Parmar, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.
- (3) This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

1.	rting Persons					
	5AM C	5AM Opportunities II (GP), LLC				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)					
	(a) \Box					
	(b) \boxtimes (1)					
3.	SEC Use Only					
4.	Citizenship or Place of Organization					
	Delaware					
		5.	Sole Voting Power			
	_		0			
Share	ber of	6.	Shared Voting Power			
Bene	ficially		1,773,000 shares (2)			
Owne Each		7.	Sole Dispositive Power			
Repo			0			
Perso	on With	8.	Shared Dispositive Power			
			1,773,000 shares (2)			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person					
	1,773,000 shares (2)					
10.	gregate Amount in Row (9) Excludes Certain Shares (See Instructions)					
11.	Percent of Class Represented by Amount in Row (9)					
	4.1% (3)					
12.	Type of Reporting Person (See Instructions)					
	00					

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.
- (3) This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

CUSIP No. 85209E109

CUSH	NO. 8	5209E109	9		
1. Names of Reporting Persons					
	Dr. Ku	sh Parma	r		
2.	Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a)				
	(b)	$\boxtimes(1)$			
3.	SEC Use Only				
4.	Citizenship or Place of Organization				
	United States				
		5.	Sole Voting Power		
			0		
Numb Shares		6.	Shared Voting Power		
Benef	cially		1,773,000 shares (2)		
Owne Each	d by	7.	Sole Dispositive Power		
Repor			0		
Persoi	n With	8.	Shared Dispositive Power		
			1,773,000 shares (2)		
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	s (2)				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				
11.	Represented by Amount in Row (9)				
	4.1% (3)				
12.	Type of Reporting Person (See Instructions)				
	IN				
(1) Thi	is Schedi	ule 13G is	s filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G		

- (1) This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.
- (3) This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

CUSIP No. 85209E109

		5209E10					
1.	Names of Reporting Persons Andrew J. Schwab						
	Andre	w J. Schw	ab				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a)						
		(b) \boxtimes (1)					
3.	SEC Use Only						
4.		Citizenship or Place of Organization					
	United	States					
		5.	Sole Voting Power				
Numł	oor of		0				
Share		6.	Shared Voting Power				
	ficially		1,773,000 shares (2)				
Owne Each	ed by	7.	Sole Dispositive Power				
Repor			0				
Perso	n With	8.	Shared Dispositive Power				
			1,773,000 shares (2)				
9.	Aggre	gate Amo	unt Beneficially Owned by Each Reporting Person				
1,773,000 shares (2)							
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)						
11.							
	4.1% (3)						
12.	Type of Reporting Person (See Instructions)						
	IN						

- (1) is Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Sc
- (2) Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.
- (3) This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

Item 1.

Item 2.

(a)	Name of Issuer					
	Spruce Biosciences, Inc.					
(b)	Address of Issuer's Principal Executive Offices					
	611 Gateway Boulevard, Suite 740 South San Francisco, CA 94080					
(a)	Name of Person Filing					
	5AM Opportunities II, L.P. ("Opps II") 5AM Opportunities II (GP), LLC ("Opps II GP") Dr. Kush Parmar ("Parmar") Andrew J. Schwab ("Schwab")					
(b)	Address of Principal Business Office or, if none, Residence					
	c/o 5AM Ventures 4 Embarcadero Center, Suite 3110 San Francisco, CA 94111					
(c)	Citizenship					
	Entities: Opps II - Delaware Opps II GP - Delaware					
	Individuals: Parmar - United States Schwab - United States					
(d)	Title of Class of Securities					
	Common Stock, par value \$0.0001 per share par value ("Common Stock")					
(e)	CUSIP Number					
	85209E109					

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Item 4. Ownership

The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:

Reporting Persons	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (2)
Opps II (1)	1,773,000	0	1,773,000	0	1,773,000	1,773,000	4.1%
Opps II GP (1)	0	0	1,773,000	0	1,773,000	1,773,000	4.1%
Parmar (1)	0	0	1,773,000	0	1,773,000	1,773,000	4.1%
Schwab (1)	0	0	1,773,000	0	1,773,000	1,773,000	4.1%

⁽¹⁾ Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.

(2) This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \boxtimes

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.



Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024

5AM Opportunities II, L.P.

By: 5AM Opportunities II (GP), LLC its General Partner

By: /s/ Kush Parmar

Name: Dr. Kush Parmar Title: Managing Member

5AM Opportunities II (GP), LLC

By: <u>/s/ Kush Parmar</u> Name: Dr. Kush Parmar Title: Managing Member

/s/ Kush Parmar

Dr. Kush Parmar

/s/ Andrew J. Schwab

Andrew J. Schwab

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

Exhibit(s):

<u>A</u> Joint Filing Agreement

EXHIBIT A

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Spruce Biosciences, Inc. is filed on behalf of each of us.

Dated: November 14, 2024

5AM Opportunities II, L.P.

By: 5AM Opportunities II (GP), LLC its General Partner

By: /s/ Kush Parmar

Name: Dr. Kush Parmar Title: Managing Member

5AM Opportunities II (GP), LLC

By: <u>/s/ Kush Parmar</u> Name: Dr. Kush Parmar Title: Managing Member

/s/ Kush Parmar Dr. Kush Parmar

DI. Kush Parmai

/s/ Andrew J. Schwab Andrew J. Schwab